Does INVESTIGATIONAL PRODUCT Cause Second primary malignancy? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Second primary malignancy have been filed in association with INVESTIGATIONAL PRODUCT. This represents 0.2% of all adverse event reports for INVESTIGATIONAL PRODUCT.
11
Reports of Second primary malignancy with INVESTIGATIONAL PRODUCT
0.2%
of all INVESTIGATIONAL PRODUCT reports
1
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From INVESTIGATIONAL PRODUCT?
Of the 11 reports, 1 (9.1%) resulted in death, 4 (36.4%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INVESTIGATIONAL PRODUCT. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does INVESTIGATIONAL PRODUCT Cause?
Febrile neutropenia (241)
Pneumonia (229)
Acute kidney injury (198)
Pyrexia (189)
Anaemia (176)
Diarrhoea (170)
Sepsis (168)
Dyspnoea (156)
Nausea (134)
Hypotension (130)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which INVESTIGATIONAL PRODUCT Alternatives Have Lower Second primary malignancy Risk?
INVESTIGATIONAL PRODUCT vs INVOKANA
INVESTIGATIONAL PRODUCT vs IOBENGUANE I-131
INVESTIGATIONAL PRODUCT vs IOBITRIDOL
INVESTIGATIONAL PRODUCT vs IODINE
INVESTIGATIONAL PRODUCT vs IODINE\IOFLUPANE I-123